• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Burning Rock Biotech Limited

    9/27/24 9:15:26 AM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    6-K 1 d865934d6k.htm FORM 6-K Form 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of September 2024

    Commission File Number: 001-39316

     

     

    BURNING ROCK BIOTECH LIMITED

    (Registrant’s Name)

     

     

    No.5 Xingdao Ring Road North, International Bio Island

    Guangzhou, Guangdong

    People’s Republic of China

    (Address of principal executive offices)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

     

     

     


    Incorporation by Reference

    This Report on Form 6-K (the “Report”) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-264577) and Form S-8 (File No. 333-251191) of Burning Rock Biotech Limited (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    2


    Exhibit Index

     

    Number

      

    Description of Document

    Exhibit 99.1    Press release

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Burning Rock Biotech Limited
    By:   /s/ Yusheng Han
    Name:   Yusheng Han
    Title:   Chief Executive Officer

     

    Date: September 27, 2024

         

     

    4

    Get the next $BNR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Burning Rock Announces Founder's Purchase of Its ADSs

    GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that as of the date of this press release, its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased US$811,721.28 of the Company's ADSs from the open market, which was conducted in compliance with the applicable rules and regulations and the Company's insider trading policy. Mr. Han's purchase of the Company's ADSs indicates his confidence in the Company's business and prospect.

    1/5/26 1:16:20 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces Results of 2025 Annual General Meeting

    GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to d

    12/22/25 11:04:44 PM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

    GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The

    12/1/25 4:11:55 AM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Burning Rock Biotech

    Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

    10/15/21 7:18:12 AM ET
    $BNR
    Medical Specialities
    Health Care

    CICC initiated coverage on Burning Rock Biotech with a new price target

    CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

    7/14/21 5:44:04 AM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    SEC Filings

    View All

    SEC Form 6-K filed by Burning Rock Biotech Limited

    6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

    12/23/25 6:11:09 AM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Burning Rock Biotech Limited

    SCHEDULE 13G - Burning Rock Biotech Ltd (0001792267) (Subject)

    12/19/25 6:00:45 PM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Burning Rock Biotech Limited

    6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

    12/1/25 9:56:48 AM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

    SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

    11/14/24 12:29:09 PM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

    2/14/24 4:05:59 PM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

    2/14/24 12:45:51 PM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Financials

    Live finance-specific insights

    View All

    Burning Rock Reports First Quarter 2024 Financial Results

    GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

    5/29/24 1:34:06 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

    GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

    5/23/24 2:00:00 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

    GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

    3/28/24 5:16:22 PM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    View All

    Burning Rock Announces Results of 2025 Annual General Meeting

    GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to d

    12/22/25 11:04:44 PM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

    GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The

    12/1/25 4:11:55 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces Results of 2024 Annual General Meeting

    GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

    12/31/24 4:56:17 AM ET
    $BNR
    Medical Specialities
    Health Care